In a nutshell The authors aimed to determine the effectiveness of enzalutamide (Xtandi ) in metastatic (cancer that has spread) hormone-resistant prostate cancer compared to the standard bicalutamide (Casodex) treatment. Some background Hormone deprivation therapy is a common treatment used in prostate cancer. It targets the...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Everolimus and bicalutamide effective in castration-resistant prostate cancer, but with side effects
In a nutshell This study examined the effectiveness of everolimus and bicalutamide in patients with castration-resistant prostate cancer. The authors concluded that the combination of these two therapies was effective, but with significant side effects. Some background Prostate cancer can be dependent on male hormones (such as testosterone)...
Read MoreIs abiraterone acetate also suitable for older men with castration resistant prostate cancer?
In a nutshell This study examined abiraterone acetate (Zytiga) as a treatment option for older men with metastatic castration-resistant prostate cancer. Researchers concluded that abiraterone acetate improves overall survival in younger as well as older men with metastatic castration resistant prostate cancer. Some background...
Read MoreHow important is drug sequence in advanced prostate cancer survival?
In a nutshell The authors aimed to determine the benefit of sequencing docetaxel (Taxotere) and abiraterone (Zytiga) treatment to improve progression-free survival (patients who did not experience cancer growth after treatment) in patients with metastaic (cancer that has spread) hormone-resistant (cancer that does not respond to hormone...
Read MoreSlowing cancer progression before chemotherapy
In a nutshell This study examined the benefit of enzalutamide (Xtandi) in treating patients with advanced prostate cancer requiring chemotherapy. Researchers concluded that enzalutamide treatment results in delayed disease progression and increased overall survival. Some background Hormone therapy is commonly used to treat prostate cancer. By...
Read MorePanitumumab treatment of progressive therapy-resistant colorectal cancer
In a nutshell This study investigated the treatment of progressive therapy-resistant colorectal cancer with panitumumab (Vectibix). It was found that panitumumab was a safe and effective treatment for CRC patients who had progressed despite treatment. Some background Chemotherapy is generally the first treatment option for colorectal...
Read MoreEffectiveness of vemurafenib treatment in advanced melanoma
In a nutshell The authors investigated the effectiveness and patient response (tolerance) to vemurafenib (Zelboraf) treatment in advanced melanoma. Some background In advanced melanoma (stage III/ IV), cancer spreads from the skin to other parts of the body (metastasis). BRAF genes are often mutated (permanently...
Read MoreLooking for patients with CHFR or micosatellite instability to receive chemotherapy combination
In a nutshell This phase 2 trial located in Maryland, United States, aims to determine whether a combination of gemcitabine (Gemzar) and docetaxel (Taxotere) is effective in patients with metastatic colorectal adenocarcinoma with CHFR and/or microsatellite instability. Patient's resposne to treatment will be measured. The details...
Read MoreComparison of pembrolizumab with chemotherapy in ipilimumab-resistant melanoma
In a nutshell The authors compared the safety and effectiveness of pembrolizumab (Keytruda) to chemotherapy for the treatment of ipilimumab (Yervoy)-resistant melanoma. Some background Ipilimumab, an immunotherapy (treatment that uses the body’s own immune system to fight cancer), is an approved drug for the...
Read MoreTargeting chemotherapy and hormone therapy resistant breast cancer
In a nutshell The authors aimed to evaluate the effectiveness of lapatinib (Tyverb) as treatment for women with metastatic breast cancer (the tumor has spread to other organs) where previous treatment has proven ineffective. Some background Circulating tumor cells (CTC’s) are cells from a primary tumor that have migrated into the blood...
Read MoreCan enzalutamide improve quality of life in hormone-resistant prostate cancer patients?
In a nutshell The authors aimed to determine the effect of enzalutamide on quality of life in patients with hormone-resistant prostate cancer after chemotherapy. Some background Hormone therapy is a common treatment used in prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Enzalutamide...
Read MoreSelumetinib in eye cancer treatment
In a nutshell The authors aimed to determine the effect of selumetinib in treating eye cancer compared to chemotherapy. Some background Uveal melanoma (eye cancer) is a rare form of cancer that occurs in the eye and has a 50% rate of metastasis (cancer spreads from the original site around the body). Selumetinib (AZD6244) is a drug that...
Read More
